Published in Cancer Weekly, August 5th, 2003
The presentation by Dr. Sanjay Goel of the Albert Einstein Medical Center, entitled "Extracellular Protein Kinase A (ECPKA) assay in cancer patients treated with multi-day continuous intravenous infusions (CIV) of GEM231, a second-generation antisense oligonucleotide targeting the PKA RIalpha subunit," was made at the 94th annual meeting of the American Association for Cancer Research being held in Washington, DC.
The study was designed to evaluate safety and effects...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.